Clinical Trial Detail

NCT ID NCT01649180
Title NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors PrECOG, LLC.
Indications

renal cell carcinoma

Therapies

Axitinib

Age Groups: adult

No variant requirements are available.